High-dose norepinephrine induces disruption of myocardial extracellular matrix and left ventricular dilatation and dysfunction in a novel feline model

Journal of the Chinese Medical Association

Volumn 69, Issue 8, 2006, Pages 343-350

  Chiu, Yung Tsung ^a   Cheng, Ching Chang ^a   Lin, Nai Nu ^a   Hung, Yi Wen ^a   Chen, Ying Tsung ^a   Hsu, Shih Lan ^a   Chi, Ching Shiang ^a   Fu, Yun Ching ^a,b  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Extracellular matrix; Heart failure; Matrix metalloproteinases; Norepinephrine

Indexed keywords

CHLORALOSE; COLLAGEN FIBER; EOSIN; GELATINASE A; GELATINASE B; HEMATOXYLIN; MATRIX METALLOPROTEINASE; NORADRENALIN; URETHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA PRESSURE; ARTICLE; CAT; CELL SHAPE; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE SIZE; HEART MUSCLE; HEART MUSCLE CELL; HEART RATE; HISTOPATHOLOGY; HYPERTROPHIC CARDIOMYOPATHY; HYPOKINESIA; M MODE ECHOCARDIOGRAPHY; NONHUMAN; SILVER IMPREGNATION; ZYMOGRAPHY;

EID: 33748511237     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/S1726-4901(09)70271-0     Document Type: Article

References (35)

1. D'Armiento J. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc Med 2002;12:97-101
2. Kim HE, Dalal SS, Young E, Legato MJ, Weisfeldt ML, D'Armiento J. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest 2000;106: 857-66.
3. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002;90:520-30.
4. Chiu YT, Liu SK, Liu M, Chen SP, Lin YH, Mao SJ, Chu R. Characterization and quantitation of extracellular collagen matrix in myocardium of pigs with spontaneously occurring hypertrophic cardiomyopathy. Cardiovasc Pathol 1999;8: 169-75.
5. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ III, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardiumn from patients with end-stage dilated cardiomyopathy. Circulation 1998;97: 1708-15.
6. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 2002;4:439-44.
7. Yokoseki O, Yazaki Y, Suzuki J, Imamura H, Takenaka H, Isobe M. Association of matrix metalloproteinase expression and left ventricular function in idiopathic dilated cardiomyopathy. Jpn Circ J 2000;64:352-7.
8. Briest W, Holzl A, Rassler B, Deten A, Baba HA, Zimmer HG. Significance of matrix metalloproteinases in norepinephrine-induced remodelling of rat hearts. Cardiovasc Res 2003;57: 379-87.
9. Barth W, Deten A, Bauer M, Reinohs M, Leicht M, Zimmer HG. Differential remodeling of the left and right heart after norepinephrine treatment in rats: studies on cytokines and collagen. J Mol Cell Cardiol 2000;32:273-84
10. Irlbeck M, Muhling O, Iwai T, Zimmer HG. Different response of the rat left and right heart to norepinephrine. Cardiovasc Res 1996;31:157-62.
11. Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res 2000;46:225-38.
12. Mann DL, Spinale FG. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation 1998;98:1699-702.
13. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
14. Li YY, Feldman AM. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications. Drugs 2001;61:1239-52.
15. Rouet-Benzineb P, Buhler JM, Dreyfus P, Delcourt A, Dorent R, Perennec J, Crozatier B, et al. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1999;1: 337-52.
16. Nishikawa N, Yamamoto K, Sakata Y, Mano T, Yoshida J, Miwa T, Takeda H, et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Cardiovasc Res 2003;57:766-74.
17. Li YY, Feng Y, McTiernan CF, Pei W, Moravec CS, Wang P, Rosenblum W, et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001;104:1147-52.
18. Rona G. Catecholamine cardiotoxicity. J Mol Cell Cardiol 1985; 17:291-306.
19. Jiang JP, Downing SE. Catecholamine cardiomyopathy: review and analysis of pathogenetic mechanisms. Yale J Biol Med 1990;63:581-91.
20. Samuels MA. Neurally induced cardiac damage: definition of the problem. Neurol Clin 1993;11:273-92.
21. Connor RC. Heart damage associated with intracranial lesions. Br Med J 1968;3:29-31.
22. Sato K, Masuda T, Izumi T. Subarachnoid hemorrhage and myocardial damage: clinical and experimental studies. Jpn Heart J 1999;40:683-701.
23. Masuda T, Sato K, Yamamoto S, Matsuyama N, Shimohama T, Matsunaga A, Obuchi S, et al. Sympathetic nervous activity and myocardial damage immediately after subarachnoid hemorrhage in a unique animal model. Stroke 2002;33:1671-6.
24. Pollick C, Cujec B, Parker S, Tator C. Left ventricular wall motion abnormalities in subarachnoid hemorrhage: an echocardiographic study. J Am Coll Cardiol 1988;12:600-5.
25. Fu YC, Chi CS, Jan SL, Wang TM, Chen PY, Chang Y, Chou G, et al. Pulmonary edema of enterovirus 71 encephalomyelitis is associated with left ventricular failure: implications for treatment. Pediatr Pulmonol 2003;35:263-8.
26. Fu YC, Chi CS, Chiu YT, Hsu SL, Hwang B, Jan SL, Chen PY, et al. Cardiac complications of enterovirus rhombencephalitis. Arch Dis Child 2004;89:368-73.
27. Khullar M, Datta BN, Wahi PL, Chakravarti RN. Catecholamine-induced experimental cardiomyopathy: a histopathological, histochemical and ultrastructural study. Indian Heart J 1989;41: 307-13.
28. Powers FM, Pifarre R, Thomas JX Jr. Ventricular dysfunction in norepinephrine-induced cardiomyopathy. Circ Shock 1994;43: 122-9.
29. Briest W, Holzl A, Rassler B, Deten A, Leicht M, Baba HA, Zimmer HG. Cardiac remodeling after long term norepinephrine treatment in rats. Cardiovasc Res 2001;52:265-73.
30. Gong CL, Chiu YT, Lin NN, Lin SZ, Cheng FC, Kuo JS. Inhibitory actions of serotonin on glutamate release in dorsal medulla suppress systemic arterial pressure of cats. Neurosci Lett 2004;355:73-6.
31. Albrechtsson U, Eskilsson J, Lomsky M, Stubbe I, Svensson SE, Tylen U. Comparison of left ventricular ejection fraction assessed by radionuclide angiocardiography, echocardiography and contrast angiocardiography. Acta Med Scand 1982;211: 147-52.
32. Romanic AM, Burns-Kurtis CL, Gout B, Berrebi-Bertrand I, Ohlstein EH. Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci 2001;68:799-814.
33. Lopez-De Leon A, Rojkind M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 1985;33: 737-43.
34. Liu SK, Chiu YT, Shyu JJ, Factor SM, Chu R, Lin JH, Hsuo HL, et al. Hypertrophic cardiomyopathy in pigs: quantitative pathologic features in 55 cases. Cardiovasc Pathol 1994;3: 261-8.
35. Baroldi G. Myocardial cell death, including ischemic heart disease and its complications. In: Silver MD, Gotlieb AI, Schoen FJ (eds). Cardiovascular Pathology, 3rd edition. Philadelphia: Churchill Livingstone, 2001:202-6.